Streptococcus pneumoniae as a genomics platform for broad-spectrum antibiotic discovery.
Streptococcus pneumoniae is a useful tool for the discovery of broad-spectrum antibiotics because of its genetic malleability and importance as a pathogen. Recent publications of complete chromosomal DNA sequences for S. pneumoniae facilitate rapid and effective use of genomics-based technology to identify essential genes encoding new targets for antibacterial drugs. These methods include computational comparative genomics, gene disruption studies to determine essentiality or identify essential genes, and gene expression analysis using microarrays and gel-based proteomics. We review how genomics has transformed the use of the pneumococcus for the pursuit of new antibiotics, and made it the best species for the identification and validation of new antibiotic targets.
Glass
John I
JI
Infectious Diseases Research and Clinical Investigation, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. Glass_John_I@Lilly.com
Belanger
Aimee E
AE
Robertson
Gregory T
GT
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015195:Drug Design; D016680:Genome, Bacterial; D023281:Genomics / Q000639:trends*; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000235:genetics*
D000900:Anti-Bacterial Agents